Aarti Pharmalabs Limited has informed the Exchange regarding Board meeting held on August 12, 2025.
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Aarti Pharmalabs' board, at its August 12, 2025 meeting, approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, revenue from operations fell to ₹37,531 lakhs (from ₹39,349 lakhs YoY, a ~4.6% decline), but net profit rose to ₹5,122 lakhs (from ₹4,714 lakhs YoY, ~8.7% growth) and EPS came in at ₹5.65 versus ₹5.20, reflecting margin expansion. Consolidated revenue dropped sharply to ₹38,619 lakhs (from ₹55,549 lakhs), though the company notes these figures are not comparable because Ganesh Polychem became a joint venture effective April 1, 2025; consolidated net profit was ₹4,950 lakhs including a ₹180 lakh share of JV loss. The board also recommended appointing M/s Mehta & Mehta as Secretarial Auditors for 5 years, re-appointing Independent Director Ms. Rupal Vora for a second 3-year term, and extending the stock option scheme to subsidiary employees. The auditor's limited review report was clean and unmodified.
The mixed quarter—lower top line but better profitability on a standalone basis—suggests margin discipline helped offset weak revenue, though the steep consolidated revenue drop (driven by JV restructuring rather than operational weakness) may draw investor questions about underlying growth. Governance items (auditor and director changes) are routine and unlikely to move the stock.